Canaccord reiterates Natera stock rating on strong Q3 results

Natera’s Q3 2026 revenue rose 34% year over year to $794 million, exceeding Canaccord Genuity’s estimates and FactSet consensus; the company raised its 2026 revenue outlook to $3.005 billion–$3.035 billion and set a $6 billion revenue target for 2029. Growth was supported by Signatera and Women’s Health, while sequential test-volume expansion no longer set records and operating expense guidance increased. Solomon Moshkevich was appointed CEO, succeeding Steve Chapman; shares were down 12.2% over the past week, and Canaccord reiterated its Buy rating and $500 target.

Analysis

The key debate is no longer whether Natera can grow, but whether growth can translate into operating leverage. Higher investment in MRD penetration and pipeline execution may support the 2029 ambition, yet it raises the bar for evidence that incremental test volume and improving gross margin can absorb operating costs. The loss of sequential test-volume acceleration is an early warning to monitor—not, by itself, proof of demand deterioration. If acceleration does not resume, a premium revenue multiple leaves the shares exposed to multiple compression even while reported revenue grows.

The CEO transition adds execution uncertainty at a point when spending and commercial priorities matter: verify whether the new CEO preserves the investment plan and delivers measurable adoption. Oncology MRD competitors, including Guardant Health and Exact Sciences, are relevant substitution and pricing checks; Women’s Health peers may also face competitive pressure if Natera sustains momentum. The article provides no share, pricing, or margin data to quantify those effects.

Near term, an earnings beat and raised outlook may cushion sentiment, but the pullback suggests investors are discounting spending and growth quality. Over 1–3 months, watch quarterly test-volume trends, gross-margin progression, and operating-expense growth against revenue. Over 6–18 months, the thesis depends on durable MRD adoption and a credible path toward profitability. Contrarian angle: the sequential acceleration pause may be a normalization after rapid expansion, not a broken growth engine; however, the revenue target is a management objective, not yet evidence of profitable execution.

Key Decisions for Investors

• Avoid chasing the headline beat. Keep NTRA on a catalyst watchlist and consider staged entry only if subsequent reporting shows continued volume growth alongside gross-margin progress and operating expenses growing more slowly than revenue.
• For existing NTRA exposure, size for valuation and execution risk; reassess if test-volume growth weakens further, guidance is cut, or gross-margin improvement stalls while operating expenses rise.
• Track the next earnings update for test volumes by business, gross margin, operating-expense trajectory, and management’s milestones for MRD adoption. These are the missing data needed to distinguish planned investment from deteriorating unit economics.
• No actionable trade in Canaccord Genuity Group is supported by this item; its reiterated rating is a broker view, not independent evidence of Natera’s commercial or financial trajectory.